A b s t r a c t
Introduction
Dopamine replacement therapy using levodopa continues to be the gold standard in the treatment of Parkinson's disease (PD). It has remained the most effective drug for the symptomatic treatment of PD since its introduction by Birkmayer and Horny Communicating author:
Dr. Khaled Radad, PhD, Department of Pathology, Faculty of Veterinary Medicine, Assiut University, Assiut 71526, Egypt, tel.: +2882333938, fax: +2882366503, email: khaledradad@hotmail.com kiewicz in 1961 [3] . Interestingly, Hurny et al. [13] have shown recently that levodopa decreased the CD 25 /CD 3 ratio, the antigen marker characteristic of apoptotic death within the T/CD 3 (+) lymphocyte population in the peripheral blood of PD patients. However, longterm levodopa treatment therapy is accompanied by abnormal involuntary movements known as levodopainduced dyskinesia [1] . More over, there is an enduring belief from preclinical studies that levodopa or its metabolite dopamine might be toxic to the remaining substantia nigra (SN) dopaminergic neurons [17] . Accordingly, de novo and younger patients might be at high risk for the development of levodopainduced compli cations as they require dopaminergic therapy for a longer period of time [8] .
Dopamine receptor agonists are the next most effective antiparkinsonian drugs after carbidopa/ levodopa medication. They are considered useful alternatives to levodopa in mild or early PD and as an additional drug in moderate to severe late disease [8] . They improve motor outcomes and decrease the risk of levodopainduced motor complications [32] . In addition to their symptomatic effectiveness, dopa mine agonists may have a neuroprotective effect. For instance, recipients of pramipexole and ropiniro le showed slower neuronal deterioration compared with levodopa recipients by means of dopamine transporter imaging using singlephoton emission computed tomography (SPECT) [21, 34] .
The nonergoline dopamine agonist rotigotine is currently approved as monotherapy in early idio pathic PD, in moderate to severe idiopathic restless leg syndrome and as adjunct therapy to levodopa in advanced idiopathic PD. In PD it is supposed to reduce motor fluctuations by constant dopaminergic stimulation using a 24h transdermal delivery sys tem (patch). Rotigotine exhibits the highest affin ity for the D 3 receptor (Ki = 0.71 nM) and acts as a full agonist at dopamine receptors (rank order:
with potencies 2,600 and 53 times higher than dopamine at dopamine D 3 and D 2L receptors [31] .
In contrast to other dopamine agonists, there is only limited knowledge of potential neuroprotective properties of rotigotine. In the acute 1methyl4 phenyl1,2,3,6 tetrahydropyridine (MPTP) mouse or progressive MPTP macaque model, the agonist was shown to exert partial protective effects on dopa minergic nerve endings [29, 30] . To date there have been no investigations exploring the direct neuro protective effects of rotigotine towards dopamin ergic neurons under conditions of inhibition of the mitochondrial respiratory chain reactions. Accord ingly, the present study was carried out in primary dopaminergic cell cultures from embryonic mouse mesencephala stressed with mitochondrial complex I blockers, MPP + and rotenone. Such studies are of interest, since the pesticide rotenone was found to be associated with an increased risk of develop ing PD [5, 33] and a subgroup of PD patients were demonstrated to exhibit a defect of complex I activ ity and structure [15, 18, 28] .
Material and methods
Preparation of primary dopaminergic cell culture
Pregnant mice (OF1/SPF, Himberg, Austria) were cared and handled in accordance with the guidelines of the European Union Council (86/609/EU) for the use of laboratory animals. At gestation day 14, uter ine horns were dissected and embryos were collect ed in Petri dishes containing sterile Dulbecco's phos phate buffered saline (DPBS, Invitrogen, Germany). Under a stereoscope (Nikon SMZ1B, 10 × magnifica tion), brains were dissected, ventral mesencephala excised and primary cultures were prepared accord ing to Radad et al. [23] . Briefly, after careful removal of the meninges, tissues were mechanically cut into small pieces in DPBS and transferred into a sterile test tube containing 2 ml of 0.1% trypsin (Invitrogen, Germany) and 2 ml of 0.02% DNase I (Roche, Ger many) in DPBS. The tube was incubated in a water bath at 37°C for 7 min. Then, 2 ml of trypsin inhibitor (0.125 mg/ml in DPBS) (Invitrogen, Germany) were added, the tissue was centrifuged (Hettich, ROTIXA/ AP) at 100 g for 4 min. The tissue pellet was triturat ed with a firepolished Pasteur pipette in Dulbecco's modified Eagle's medium (DMEM, Sigma, Germany) containing 0.02% DNase I. Dissociated cells were collected in DMEM supplemented with Hepes buffer (25 mM), glucose (30 mM), glutamine (2 mM), pen icillinstreptomycin (10 U/ml and 0.1 mg/ml, respec tively) and heat inactivated foetal calf serum (FCS, 10%) (all from Sigma, Germany). The cell suspension was plated into fourwell multidishes (Nunclon, Ger many) precoated with polyDlysine (50 µg/ml) (Sig ma, Germany). Cultures were grown at 37°C in an atmosphere of 5% CO 2 /95% air and 100% relative humidity. The medium was exchanged on the 1 st day in vitro (DIV) and on the 3 rd DIV. On the 5 th DIV half of the medium was replaced with serumfree DMEM containing 0.02 ml of B27/ml (Invitrogen, Germa ny). Serumfree supplemented DMEM was used for feeding from the 6 th DIV and subsequently replaced every 2 nd day.
Treatment of cultures with rotigotine, MPP + and rotenone
To investigate the effect of rotigotine (UCB, Bel gium) on the survival of THir neurons, primary mes encephalic cell cultures were treated with different concentrations of rotigotine (0.01, 0.1, 1 and 10 µM) from the 6 th DIV for 8 consecutive days. Rotigotine was added with each change of the culture medi um every second day from a fresh stock solution (10 mM) prepared in DMSO (0.1% final concentra tion). To investigate the effect of rotigotine against MPP + or rotenoneinduced cell death, rotigotine was added from the 6 th DIV until the 14 th DIV as describ ed above and MPP + (10 µM) or rotenone (20 nM) were coadministered on the 12 th DIV for 48 h.
Identification of THir neurons
Dopaminergic neurons were identified immuno cytochemically by staining tyrosine hydroxylase. Cul tures were rinsed carefully with phosphate buffered saline (PBS, pH 7.2) at the end of each treatment and fixed in 4% paraformaldehyde for 45 min at 4°C. After washing with PBS, cells were permeabilized with 0.4% Triton X100 for 30 min at room temper ature. Cultures were washed 3 times with PBS and incubated with 5% horse serum (Vectastain ABC Elite kit) for 90 min to block nonspecific binding sites. To determine the number of THir in cultures, cells were sequentially incubated with antiTH primary antibody overnight at 4°C, biotinylated secondary antibody (Vectastain) and avidinbiotinhorseradish peroxidase complex (Vectastain) for 90 min at room temperature and washed with PBS between stages. The reaction product was developed in a solution of diaminobenzidine (1.4 mM) in PBS containing 3.3 mM of hydrogen peroxide (H 2 O 2 ) and stained cells were counted with a Nikon inverted microscope in 10 randomly selected fields (1.13 mm 2 = field) in each well at 10× magnification. On the 14 th DIV, the average number of THir cells in the various experi ments was between 1000 and 1500 cells/well.
Measurement of ROS with CH-H 2 DCFDA
When the production of ROS was measured, cultures were treated with rotigotine (0.01 µM, the protective concentration against rotenone) from the 6 th DIV until the 12 th DIV. Rotenone (20 nM) was coadministered on the 12 th DIV for 48 h. On the 14 th DIV cultures were washed and incubated with 5 µM of the fluorescence indicator, 5(and 6)chlo romethyl2',7'dichlorodihydrofluorescein diacetate (CHH 2 DCFDA), for 30 min and ROS was measured according to Radad et al. [24] . In short, cultures were rinsed twice with colourless medium and photo graphed on a Nikon inverted microscope equipped with epifluorescence attachment using a rhodamine filter set (510 DM/520 BA, B2A) and a Coolpix 990 digital camera (Nikon, Japan). In each experiment, four wells were cultivated for each treatment con dition. Five micrographs were taken from each well. Ten cell bodies were randomly selected by a blinded researcher from each micrograph (meaning that 200 cells were evaluated for each treatment condition in each of three independent experiments) and the average density for 100 pixels in individual cell bodies was determined using Adobe Photoshop software ® .
Statistical analysis
Data were expressed as mean ± standard error of mean (SEM). Statistical significance was calculated using the KruskalWallis (H)test followed by χ 2 . Dif ferences with p < 0.05 were regarded as statistically significant.
Results

Effect of rotigotine on the survival of dopaminergic neurons
Addition of rotigotine (0.01, 0.1, 1 µM) for 8 con secutive days produced no effect on the number of THir neurons in primary mesencephalic cell culture compared to untreated controls. However, rotigotine decreased the number of THir neurons by 40% when added at an unphysiological high concentration of 10 µM (Fig. 1) .
Rotigotine slightly protected dopaminergic neurons against MPP + toxicity MPP + (10 µM) decreased the number of THir neu rons by 43% compared to untreated control cultures Fig. 1 . Effect of incubation with various con centrations of rotigotine on the survival of THir neurons. Treatment was begun on the 6 th DIV for 8 consecutive days with a change of medi um together with rotigotine every 2 nd day. 100% corresponds to the total number of dopaminer gic neurons after a cultivation period of 14 days without rotigotine treatment. Values represent the mean ± SEM of three independent experi ments in quadruplicate. *p < 0.0001 compared to untreated control. Fig. 2A) . After MPP + treatment, surviving neurons had shortened and thickened neurites as well as atro phied cell bodies (Fig. 2B) . The treatment of cultures with 0.01 µM rotigotine attenuated MPP + induced toxicity by increasing the number of dopaminergic neurons by 10%, although this effect did not reach significance ( Fig. 2A) .
Rotigotine significantly protected dopaminergic neurons against rotenone-induced cell death
The treatment of cultures with 20 nM rotenone decreased the number of THir neurons by 55% com pared to untreated control cultures (Fig. 3A) . After rotenone treatment, surviving neurons exhibited less and shortened neurites (Fig. 3B) . On the other hand, 0.01 µM rotigotine was able to counteract rote noneinduced toxicity by significantly increasing the number of dopaminergic neurons by 20% (Fig. 3A) .
Rotigotine significantly inhibited ROS production by rotenone
The formation of ROS in cultures was meas ured using CMH 2 Fig. 3 . A) Effect of rotigotine on the number of dopaminergic neurons after treatment with rotenone. Treat ment with rotigotine was begun on the 6 th DIV for 8 consecutive days with a change of medium together with rotigotine every 2 nd day. Rotenone (20 nM) was additionally added for 48 h from 1214 th DIV. 100% corresponds to the total number of dopaminergic neurons after a cultivation period of 14 days without any treatment. Values represent the mean ± SEM of three independent experiments in quadruplicate. ( # p < 0.0001 compared to untreated controls, *p < 0.0001 compared to rotenonetreated cultures). B) Repre sentative micrographs of THir neurons after 14 DIV. Control cultures were cultivated without any treatment while for rotenone treatment, cultures were incubated with rotenone for 48 h from 1214 th DIV.
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ROS production by 63% (Fig. 4A) as reflected in high er fluorescence density compared to untreated con trol culture (Fig. 4B) . Rotigotine (0.01 µM, on the 6 th DIV for six days) significantly decreased the intracel lular production of ROS by 17% compared to rote nonetreated cultures (Fig. 4A) . Figure 4B showed that treatment of cultures with rotigotine (0.01 µM) decreased the fluorescence density of CMH 2 DCFDA compared to rotenonetreated cultures.
Discussion
Protection of dopaminergic neurons by dopa mine agonists has been a topic of interest for the past 20 years. While the lack of placebo groups in clinical studies did not allow a definite conclu sion with respect to the neuroprotective effect of the do pamine agonists ropinirole and pramipex ole [21, 34] , numerous preclinical studies were able to demonstrate distinct neuroprotective effects in animal or cell culture models [22, 26, 27] . In the pres ent study, primary mesencephalic cell cultures were used to investigate the neuroprotective potential of the nonergot dopamine agonist rotigotine against MPP + and rotenone toxicity. Both components are known inhibitors of complex I of the mitochon drial respiratory chain [20, 25] and the detection of a defect in complex I in the SN of idiopathic PD cas es provided a direct link to the MPTP (respectively MPP + ) and rotenone toxicity models.
In preliminary experiments, the effect of rotigo tine on the survival rate of THir neurons was inves tigated. In a concentration range up to 1 µM, rotigo A B tine, when given for eight consecutive days, did not affect the survival of THir neurons. These results are similar to those achieved with the D 2 receptor ago nist αdihydroergocryptine that showed no stimula tion of THir neurons, but differ from the D 2 receptor agonist lisuride which significantly enhanced the number of THir neurons under the same treatment conditions [9, 11] . Treatment with 10 µM rotigotine decreased the number of THir neurons, which is similar to the behaviour of the D 2 agonist pergolide and αdihydroergocryptine [9, 10] . However, the high unphysiological concentration of 10 µM exceeds by far the therapeutic doses of 116 mg/day and the achieved plasma concentrations of unconjugated rotigotine which amount up to 1 ng/ml [7] .
Some dopamine agonists have exhibited neuro protection for dopaminergic neurons against MPTP in mice, for example bromocriptine [19] and prami pexole [16] . Neuroprotection against MPP + in prima ry dopaminergic culture from embryonic mouse or rat mesencephalon was demonstrated for lisuride [11] , and pramipexole and ropinirole, respectively [6] . In contrast to these findings, rotigotine was not able to significantly counteract MPP + induced toxici ty for dopaminergic neurons.
Since Betarbet et al. used the highly selective com plex I inhibitor rotenone to reproduce PD's features in rats [2] , rotenone has been considered a model neuro toxin for PD both in vitro and in vivo. Similar to our pre vious work [24] , treatment of primary mesencephalic cell culture with 20 nM rotenone killed about 50% of dopaminergic neurons. Rotenoneinduced cell death was shown to be attributed to overproduction of ROS and a decreased mitochondrial membrane potential [24] . Here we show that rotigotine was able to protect dopaminergic neurons from rotenone toxicity which might at least be partially attributed to a significant suppression of ROS production induced by rotenone treatment. Other dopamine agonists like pramipexole and ropinirole protected against rotenoneinduced cell death in the dopaminergic neuroblastoma cell line SHSY5Y [4, 12] and pramipexole protected also against nigrostriatal dopaminergic degeneration and motor deficits in rotenonetreated mice [14] .
In conclusion, rotigotine significantly protects dopaminergic neurons against rotenone toxicity in primary mesencephalic cell culture. The mechanism of protection involves counteracting of mitochon drial dysfunction as rotenoneinduced radical pro duction can be prevented by rotigotine.
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